Molecular Staging
Latest round
- Series D
Last raised
- Dec 2000
Total raised
- $41M
Investors
- 6
About Molecular Staging
Molecular Staging, Inc.Molecular Staging, Inc. was founded in 1998 and is headquartered in New Haven, US. The company focuses on developing technologies for the detection of biomarkers related to cancer and other diseases. In September 2004, Qiagen acquired Molecular Staging, Inc.Molecular Staging Inc. (MSI) specializes in advanced life sciences technologies that focus on the detection and quantification of proteins and nucleic acids. The company's core offerings include Rolling Circle Amplification Technology (RCAT™), which facilitates ultra-sensitive diagnostics for a range of medical conditions including cancer, infectious diseases, neuropsychiatric disorders, and autoimmune disorders. RCAT™ enhances diagnostic capabilities by amplifying the signal from minute quantities of target molecules, such as DNA, RNA, and proteins, allowing for earlier disease detection. MSI's high-coverage protein microarrays and whole-genome amplification services serve analytical needs in various healthcare markets, enabling researchers and clinicians to conduct thorough studies on multiple proteins simultaneously and renew DNA samples for ongoing testing.Molecular Staging operates within a business model that includes partnerships and collaborations with healthcare providers and research institutions. Their revenue is generated primarily through the sale of diagnostic tests and services, including their flagship RCAT™-based assays and protein microarrays. Transactions typically occur through contractual agreements with clients in the healthcare sector, where services are provided on a per-test basis or through subscription models for ongoing diagnostic needs. Pricing structures are aligned with the specialized nature of the offerings, reflecting the advanced technology and precision involved in the diagnostics.Molecular Staging, Inc. plans to enhance its product offerings by developing new diagnostic assays leveraging their proprietary RCAT™ technology. The company aims to expand into Asian markets by 2025.
Who invested in Molecular Staging
6 investors across 1 round
See all investors in Molecular Staging
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series D
Dec 19, 2000
Amount
$41M
Investors
Questions about Molecular Staging
Who invested in Molecular Staging?
Molecular Staging has 6 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Molecular Staging raised?
Molecular Staging has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Molecular Staging last raise money?
Molecular Staging's most recent round on record is a Series D, in Dec 2000.
What does Molecular Staging do?
Molecular Staging is a biotechnology company.
Where is Molecular Staging headquartered?
Molecular Staging is headquartered in New Haven, US.
Which VCs invest in companies like Molecular Staging?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Molecular Staging's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Molecular Staging? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.